Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System Workshop Summary (2011) / Chapter Skim
Currently Skimming:
1 Introduction
1 Introduction
Pages 1-4
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 1... ...
A workshop titled Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System was convened by the Institute of Medicine Forum on Neuroscience and Nervous System Disorders to explore promising current and emerging technologies with potential as reliable glutamate biomarkers, and to outline strategies to 1 This workshop was organized by an independent planning committee whose role was limited to the identification of topics and speakers. This workshop summary was prepared by the rapporteurs as a factual summary of the presentations and discussions that took place at the workshop.
|
From page 2... ...
Daniel Javitt, director of schizophrenia research at the Nathan Kline Institute for Psychiatric Research and cochair of the workshop, stressed that development of glutamate biomarkers has the potential to increase the understanding of glutamate dysfunction in CNS disease. Biomarkers would provide a mechanism to: • m onitor response to treatment; • i dentify people at risk for disease; • m easure and predict disease progression or prognosis; • i dentify molecules sufficiently important to the disease that they are strong targets for treatment or prevention; • o ffer a choice of outcome measures in "proof-of-concept" studies to spur investment and lead to larger clinical trials; 2 Memantine is indicated for cognitive dysfunction in Alzheimer's disease, ketamine is an anesthetic, and D-cycloserine is indicated for anxiety disorders, schizophrenia, and chronic pain.
|
From page 3... ...
This workshop featured more than 20 presentations describing new approaches to biomarker development while recognizing that the research remains in the hypothesis testing and replication stages. Specific objectives of the workshop were as follows: • B riefly outline the need for glutamate-related biomarkers both for understanding the causes of neuropsychiatric disorders and neu rodegenerative diseases associated with glutamatergic dysfunction and for accelerating drug development for these disorders.
|
From page 4... ...
The report that follows highlights the presentations by the expert panelists, and the open panel discussions that took place during the workshop. This report is not intended to be a thorough review of all published literature but an accounting of speaker presentations and commentary by panelists and workshop attendees.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.